| B38 | HIV-1 subtype influences the selection of resistance mutations and the resistance level to integrase inhibitors | E-poster | Antiretroviral drug resistance |
| D96 | Robust progress in ARV optimization for older adolescents and adults despite COVID-19 | E-poster | Antiretroviral therapy, including treatment as prevention |
| D96 | Impact of rapid antiretroviral therapy initiation on treatment response in men who have sex with men in West Africa (CohMSM ANRS 12324 ' Expertise France) | E-poster | Antiretroviral therapy, including treatment as prevention |
| D96 | Pediatric ARV optimization in a real-world setting: Dolutegravir transition in Mozambique | E-poster | Antiretroviral therapy, including treatment as prevention |
| D96 | Access to antiretroviral therapy for people living with HIV and associated factors in Cameroon: a cross sectional study | E-poster | Antiretroviral therapy, including treatment as prevention |
| D96 | TLD turnaround: increasing rates of Dolutegravir-based regimens among women of childbearing age in Zimbabwe | E-poster | Antiretroviral therapy, including treatment as prevention |
| D96 | Stigma, survival, and social support: exploring lived experiences of antiretroviral therapy among young gay and bisexual men, sex workers, and transgender women living with HIV in Jamaica | E-poster | Antiretroviral therapy, including treatment as prevention |
| B7 | A rapid enzymatic assay for selective detection of HIV drugs that indicate long-term and short-term PrEP adherence | Oral abstract session with live Q&A | ART adherence measurement |
| B7 | No difference in urine tenofovir levels in patients living with HIV on unboosted vs dose-adjusted boosted tenofovir alafenamide | E-poster | ART adherence measurement |
| B7 | Effect of digital adherence tools on adherence to antiretroviral treatment among adults living with HIV in Kilimanjaro, Tanzania: a randomised controlled trial | E-poster | ART adherence measurement |